Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860582 | 1.00 | CHRM2 (0.49) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL20989610 | 0.87 | GPR119 (0.51) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL720548 | 0.86 | CHRM2 (0.49) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL10052777 | 0.86 | CHRM2 (0.49) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL720547 | 0.86 | CHRM2 (0.49) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL30311912 | 0.83 | GPR119 (0.38) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL719336 | 0.83 | GPR119 (0.47) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL10052776 | 0.83 | GPR119 (0.47) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL719335 | 0.83 | GPR119 (0.47) | CHRM2CHRM1CHRM3GPR119HSD11B1 | |
| SCHEMBL25173818 | 0.83 | KCNH2 (0.38) | CHRM2CHRM1CHRM3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368163-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4396177-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023034827-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-4110774-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4110771-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2021174176-A9 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2021174170-A9 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368163-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | CHRM2 4815/4885CHRM1 4610/4885CHRM3 4393/4885 |
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | CHRM2 4760/4885CHRM1 4390/4885CHRM3 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.